Tommy Thompson to Helm Biotech Firm, Targeting Drug Delivery's Frontier

MEQUON, WI – April 30, 2026 – In a move that fuses political capital with scientific ambition, former Wisconsin Governor and U.S. Health and Human Services Secretary Tommy Thompson has been named Chairman of the Board for Vector Science & Therapeutics. The appointment places one of the most influential figures in modern American healthcare policy at the helm of a young Wisconsin-based biotech company aiming to revolutionize how medicines are delivered.

Vector Science & Therapeutics, founded in 2024, announced the high-profile appointment today, signaling a significant strategic pivot as it works to advance its transdermal drug delivery platforms. The company, which focuses on creating targeted therapies for pain management, orthopedics, cancer, and regenerative medicine, hopes to leverage Thompson's immense experience to navigate the complex regulatory and commercial landscapes of the pharmaceutical industry.

"We are honored to welcome Tommy Thompson as Chairman of our Board," said Bill Jackson, Chief Executive Officer of Vector Science & Therapeutics. "His unparalleled experience in healthcare policy, combined with his deep understanding of Wisconsin's innovation ecosystem, makes him the ideal leader to guide Vector's strategic direction."

From Public Service to a New Biotech Mission

Tommy Thompson's career is a storied chronicle of public service. As Wisconsin's longest-serving governor from 1987 to 2001, he was known for championing economic development, particularly in the state's nascent biotech sector. His move to Washington, D.C. to serve as HHS Secretary under President George W. Bush from 2001 to 2005 placed him at the center of major national healthcare initiatives, including the implementation of the Medicare Prescription Drug Benefit (Part D) and efforts to modernize the nation's health infrastructure.

His transition into the private sector has seen him serve on the boards of several prominent healthcare companies, including HealthPeak Properties and TherapeuticsMD, giving him deep insight into corporate governance and the challenges of medical commercialization. Now, he brings that formidable resume to a startup with ambitious goals.

"Vector Science & Therapeutics represents exactly the kind of innovative thinking we need to address the challenges facing modern healthcare," Thompson stated in the announcement. He highlighted the growing need for targeted therapies in an aging population often dependent on multiple medications, or polypharmacy. "Vector's transdermal drug delivery platforms will deliver significant advances in targeted therapy delivery, offering the potential to improve treatment efficacy while minimizing systemic side effects."

For a young company, Thompson's involvement is more than just a name on the letterhead. His expertise is a critical asset for navigating the U.S. Food and Drug Administration (FDA), an agency whose processes can make or break emerging medical technologies. His deep connections in both public and private healthcare spheres could unlock partnerships and strategic alliances crucial for growth.

The Science of Precision Delivery

Vector is stepping into a highly competitive but rapidly growing field. The global transdermal drug delivery market, valued at over $62 billion in 2023, is projected by some analysts to reach nearly $137 billion by 2030. The demand is driven by a desire for non-invasive, patient-friendly alternatives to pills and injections that can provide a steady, controlled release of medication while avoiding the harsh side effects associated with systemic drug exposure.

However, the skin is a formidable barrier, and for decades, only a handful of drugs have been successfully formulated into patches. Vector aims to overcome this limitation with what it calls "active transdermal" platforms. The company's approach seeks to be "Smart, Steered, and Sustained," utilizing technology that may incorporate AI-enabled biofeedback, ultrahigh-frequency electrotherapy, and focused magnetic fields to deliver therapies precisely where they are needed.

This technology is designed to create non-systemic, localized interventions for conditions where delivering a drug throughout the entire body is either ineffective or causes unacceptable harm. By focusing on pain, orthopedics, and even cancer, Vector is targeting areas where precision is paramount. The goal is to maximize the therapeutic effect at the site of disease or injury while minimizing the collateral damage that often complicates treatment.

A Strategic Play on a Volatile Market

While the science is ambitious, the business realities are stark. Vector Science & Therapeutics is a pre-revenue entity that only recently began trading on Canada's TSX Venture Exchange under the fitting ticker symbol "PAIN." The company went public through a reverse takeover of a capital pool company, a common path for early-stage ventures to access public markets. Its stock has been volatile, and with a market capitalization fluctuating in the tens of millions, it is a minnow swimming in an ocean dominated by pharmaceutical giants like Novartis, Johnson & Johnson, and 3M, all of whom are major players in the transdermal space.

In this context, Thompson's appointment is a calculated masterstroke of corporate strategy. For a company with no analyst coverage and a limited public track record, bringing a former HHS Secretary on board is a powerful signal to investors. It lends immediate credibility and suggests a well-thought-out plan for surmounting the immense regulatory and commercial hurdles that lie ahead. The appointment is designed to attract sophisticated capital, build confidence, and assure the market that the company is serious about its long-term vision.

As he expressed excitement to "help advance these breakthrough technologies," Thompson is not just joining a board; he is lending his name and reputation to a high-risk, high-reward venture. The path from a developmental-stage concept to a widely adopted medical product is long and fraught with peril, requiring successful clinical trials, robust manufacturing, and savvy marketing. For the nascent company, Thompson's appointment is not just a headline; it's a calculated move to turn scientific potential into clinical and commercial reality.